Luxembourg-based Creabilis SA has raised €15 million in a Series B round led by Abbott Biotech Ventures to develop its lead product for psoriasis and atopic dermatitis, CT327, to the end of Phase 2. CT327 is a topically applied treatment. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals